This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in participants with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).
Medical Condition
Study Phase
Intervention Type
Date
Gender
Age
Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
You can ask us questions via online form or phone call.
Call us @: 844 663-3742
Location | Status | Site Contact Details |
---|---|---|
Location Eye Center South, Dothan, Alabama, 36301 | Status Not Available | Site Contact Details |
Location Arizona Eye Center, Chandler, Arizona, 85224 | Status Not Available | Site Contact Details |
Location Walman Eye Center, Chandler, Arizona, 85225 | Status Not Available | Site Contact Details |
Location Shasta Eye Medical Group, Inc., Redding, California, 96002 | Status Not Available | Site Contact Details |
Location Wolstan & Goldberg Eye Associates, Torrance, California, 90505 | Status Not Available | Site Contact Details |
Location Eye Associates of Colorado Springs, Colorado Springs, Colorado, 80909 | Status Not Available | Site Contact Details |
Location West Coast Eye Institute, Lecanto, Florida, 34461 | Status Not Available | Site Contact Details |
Location Emory University Eye Center, Atlanta, Georgia, 30322 | Status Not Available | Site Contact Details |
Location Coastal Research Associates, LLC, Roswell, Georgia, 30076 | Status Not Available | Site Contact Details |
Location The Eye Care Institute, Louisville, Kentucky, 40206 | Status Not Available | Site Contact Details |
Location Fraser Eye Center, Fraser, Michigan, 48026 | Status Not Available | Site Contact Details |
Location Galanis Cataract and Laser Eye Center, Saint Louis, Missouri, 63119 | Status Not Available | Site Contact Details |
Location Ophthalmic Consultants of Long Island, Lynbrook, New York, 11563 | Status Not Available | Site Contact Details |
Location Asheville Eye Associates, Asheville, North Carolina, 28803 | Status Not Available | Site Contact Details |
Location James D. Branch MD, Winston-Salem, North Carolina, 27101 | Status Not Available | Site Contact Details |
Location Bergstrom Eye Research, LLC, Fargo, North Dakota, 58103 | Status Not Available | Site Contact Details |
Location Scott & Christie and Associates, PC, Cranberry Township, Pennsylvania, 16066 | Status Not Available | Site Contact Details |
Location The Cataract & Glaucoma Center, El Paso, Texas, 79902 | Status Not Available | Site Contact Details |
Location DCT- Shah Research, Mission, Texas, 78572 | Status Not Available | Site Contact Details |
Location San Antonio Eye Center, San Antonio, Texas, 78215 | Status Not Available | Site Contact Details |
Location Vistar Eye Center, Roanoke, Virginia, 24016 | Status Not Available | Site Contact Details |
Location CHU de Bordeaux Hopital Pellegrin Service Ophtalmologie, Bordeaux, 33076 | Status Not Available | Site Contact Details |
Location Centro de Oftalmologia Barraquer, Barcelona, 8021 | Status Not Available | Site Contact Details |
Location Hospital Clinico San Carlos, Madrid, 28040 | Status Not Available | Site Contact Details |
This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in participants with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).
Intraocular Pressure (IOP) at Baseline
Time Frame: Baseline (prior to treatment)
Change From Baseline in IOP at Week 4
Time Frame: Baseline (prior to treatment) to Week 4
Change From Baseline in IOP at Week 12
Time Frame: Baseline (prior to treatment) to Week 12
Change From Baseline in Intraocular Pressure (IOP) at Week 24
Time Frame: Baseline (prior to treatment) to Week 24
Change From Baseline in IOP at Weeks 8, 15, and 20
Time Frame: Baseline (prior to treatment) to Weeks 8, 15 and 20
Time to Initial Use of Nonstudy IOP-lowering Treatment as Determined by the Investigator
Time Frame: First treatment to end of study (up to 525 days)
Percentage of Participants With Eyes Achieving a ≥ 20% Reduction in IOP
Time Frame: Baseline (prior to treatment) to Cycle 1: Day 2, Weeks 4, 8, 12, 15, 20, 24, 28, 31, 36, 40, 44, 47, 52; Cycle 2:Day 2, Weeks 4, 8, 12, 15, 20, 24, 28, 31, 36; Cycle 3: Day 2, Weeks 4, 8, 15, 20
Interventions:
Enrollment:
144
Watch a video to learn more about what you may experience as a clinical trial volunteer: /resources/what-happens-in-a-clinical-trial
Take a virtual reality screening visit tour to an example of a clinical trial site: /resources/screening-visit-virtual-tour
Use a questionnaire tool to think through questions to ask yourself about participating in a clinical trial and print out your responses to discuss with your partners in your health journey: /resource-information-clinical-trial-community/decision-counselor
AbbVie Clinical Trials is designed to support, inform, and help patients in a clinical study or those who are interested in participating.
Please note that the information on this website is intended for informational purposes only and should not be used as a substitute for seeking medical advice or treatment from a healthcare professional. You should not use this information to diagnose or treat a medical condition or health problem. Speak to a healthcare professional if you have any questions about your health, medical condition, symptoms, or treatment options.
Copyright © 2024 AbbVie Inc.